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Clinical pharmacology of HIV protease inhibitors: 
focus on saquinavir, indinavir, and ritonavir
• R.M .W . Hoetelm ans, P.L. Meenhorst, J.W . Mulder, D .M . Burger, C ,H .W . Koks 
and J.H , Beijnen
Introduction
The Acquired Immune Deficiency Syndrome (AIDS) as 
a disease was first noted in 1981 when the Center for 
Disease Control reported rare forms of pneumonia 
and skin cancer in young gay men in California and 
New York [1 2), The identification and isolation of 
the Human Immunodeficiency Virus (HIV) as the caus­
ative agent of the disease in 1983 led to the initiation 
of drug development efforts. These efforts yielded the 
first effective drug, zidovudine, a reverse transcriptase 
inhibitor, in 1987 [3], In the following years other 
reverse transcriptase inhibitors were introduced 
(didanosine, zalcitabine, lamivudine, stavudine) and 
until recently monotherapy or combination therapy 
regimens with these drugs were the mainstay of anti­
retroviral therapy.
However, the beneficial effects of (combinations of) 
these drugs are only temporarily [4 5]. Recently, two 
new classes of potent antiretroviral drugs, the non­
nucleoside reverse transcriptase inhibitors and the 
protease inhibitors, were introduced and tested in 
clinical trials. The non-nucleoside reverse transcrip­
tase inhibitors will not be discussed here.
The protease inhibitors show the potential of sup­
pression of HIV not seen hitherto and this has led to 
discussion whether there is now the opportunity to 
change AIDS from a fatal to a chronic disease, or even 
to eradicate the virus.
The protease inhibitors comprise a heterogeneous 
class of compounds that target another stage of the 
HIV life cycle than the reverse transcriptase inhibitors. 
Therefore, combination of protease inhibitors and 
reverse transcriptase inhibitors is an attractive option 
to suppress HIV replication.
Protease inhibitors are in general well tolerated 
drugs that do not show overlapping toxicities with 
reverse transcriptase inhibitors. Protease inhibitors are 
extensively metabolised by cytochrome P450 
enzymes. Thus, the potential of drug-drug interac­
tions is evident [6], Package inserts for protease inhib­
itors identify numerous potential drug-drug interac­
tions.
Cross-resistance between protease inhibitors may 
raise problems in the near future.
In this review we describe the pharmacology of HIV 
protease inhibitors, and focus on saquinavir, indinavir, 
and ritonavir. Clinical results with these compounds 
are evaluated. Furthermore, adverse effects, resis­
tance, dosage and administration, clinical pharma­
cokinetics, pharmacokinetic-pharmacodynamic rela­
tionships, and drug-drug interactions are discussed.
HIV protease function
Human immunodeficiency virus (HIV) carries most of 
its genetic information in three genes: gag, pol and 
env. Gag encodes the proteins of the core and nucle- 
ocapsid; pol encodes the enzymes involved in viral
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Abstract
In this review the clinical pharmacology of HIV protease inhi­
bitors, a new class of antiretroviral drugs, is discussed. After 
considering HIV protease function and structure, the deve­
lopment of inhibitors of HIV protease is presented. Three pro­
tease inhibitors are reviewed in more detail: saquinavir, indi­
navir, and ritonavir. Clinical trial results with these agents are 
evaluated. Furthermore, adverse effects, resistance, dosage 
and administration, clinical pharmacokinetics, pharmacoki­
netic-pharmacodynamic relationships, and drug interactions 
are discussed.
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replication: reverse transcriptase, ribonuclease H, 
integrase and protease, and env encodes the enve­
lope glycoproteins [7]. These genes are expressed as 
large precursor proteins, which undergo posttransla- 
tional processing. The env pofyprotein is cleaved by 
host cellular enzymes. The polyproteins encoded by 
the gag and pol genes are proteolytically cleaved by 
an HIV-encoded protease* The gag precursor protein 
is translated directly from the gag gene and is cleaved 
by HIV protease into four proteins of the interior vir­
ion. The poi gene, however, is not directly translated 
into a precursor pol protein. The replicative enzymes 
encoded by the poi gene are cleaved from a large 
fusion protein of gag-pol. Translation of this fusion 
protein occurs less frequently than translation of the 
gag gene. The replicative enzymes can only be 
formed from this fusion protein, since an overlap of 
genetic information between the gag and pol genes 
exists. The protease first cleaves itself out of the gag- 
pol fusion protein. Afterwards, the protease processes 
precursor proteins to yield structural proteins and rep­
licative enzymes (Figure 1 ) [7].
Inhibition of HIV protease activity leads to produc­
tion of non-infectious virions, which have the mor­
phological features of immature particles [8],
In vitro studies have shown that other substrates 
may serve as substrates of HIV protease, including 
cytoskeletaf and sarcomeric proteins, calmodulin, 
NFkB and fibronectin [9]. The significance of protease 
activity on the cytopathic effects of HIV infection in 
vivo with respect to these observations is not clearyet.
HIV protease structure
Generally, proteases can be classified into four groups 
based on the structure of the active site: the aspartic, 
cysteine, serine and metallo proteases [10]. HIV pro­
tease is an aspartic protease. The enzyme is a bilobal 
protein, comprising two identical 99-amino acid 
monomers. The HIV protease is a symmetric C2 dinner. 
Each monomer contributes a highly conserved part, 
Asp-Thr-Gly, to the active site. The active site is locat­
ed where the two lobes of the monomers are joined 
[11].
Mammalian proseases of the aspartic group (like 
renin and pepsin) are also bilobal proteins. However, 
these are asymmetric enzymes. The symmetric nature 
of the HIV protease and the lack of symmetry of mam­
malian proteases have been utilized in the search for 
selective inhibitors of HIV protease.
Five non-contiguous regions of the HIV protease 
are highly conserved across isolates of HIV-1. These 
regions are associated with important characteristics 
of the enzyme: the substrate-binding region and the 
catalytic site [9]. At the amino acid level, HIV-2 and 
SIV (simian immunodeficiency virus) vary ~ 50% from 
HIV-1. However, most of the amino acid variations 
occur outside the catalytic site [12]. Therefore, it may 
be not surprising that protease inhibitors show activ­
ity against HIV-2 in vitro [13].
Developm ent of HIV protease inhibitors
Early inhibitors of HIV protease were peptidyl ana­
logues that were used as inhibitors of renin. These 
early peptidyl analogues showed poor stability 
(owing to the vulnerability to degradative enzymes), 
low oral bioavailability (due to poor solubility in both 
water and lipids) and rapid hepatic metabolism [7], 
Next step was to design agents that mimic the transi­
tion state of the amide bond hydrolysis, resulting in 
increased stability. Furthermore, it was tried to reduce 
these agents in size to increase bioavailability. 
Computer-aided drug design has been used to search 
for inhibitors once the crystal structure of the HIV pro­
tease was elucidated [14 15]. Structure-based search 
has provided several C2 symmetric inhibitors. These 
agents show more affinity to the viral protease than to 
their physiological substrates. Furthermore, these 
symmetric compounds show less affinity to the asym­
metric mammalian proteases, thus increasing speci­
ficity. In general, efforts to improve bioavailability (by 
increasing water solubility) resulted in decreased anti­
viral activity. Thus, a balance between acceptable bio­
availability and sufficient inhibitory activity had to be 
pursued [7].
At this moment, approximately 30 protease inhibi­
tors are under (pre)clinical investigation. Three pro-
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Figure 1
HIV-1 genome and the processing of the gag and pol genes.
Table 1 Effects of saquinavir monotherapy on CD4+ lymphocyte counts and HiV RNA load
Reference change in CD/ lymphocyte count from baseline change in HIV RNA load from baseline
(cells/fjL) (f0!og units)
dose 
(mg tid)
patients (N) maximum week of 
maximum
change at week 
16 24
maximum week of 
maximum 
•
change
16
at week 
24
17 IS 10 +23 4 -29 -0.10 12 -0.0 7
(013328) 75 12 +30 3 -31 -0.07 4 +0.15
200 12 +68 3 -20 -0.40 4 -0.30
600 10 +104 6 +36 -0.70 8 -0.05
18 75 14 -36
(V13329) 200 17 -22
600 14 +6
19 3600 mg/day 20 +72 4 +31 -1.06 2 -0.48
7200 mg/day 20 +121 20 +82 -1,34 4 -0.85
tease inhibitors are now available and will be dis­
cussed in more detail: saquinavir, indinavir, and riton­
avir.
Saquinavir
Saquinavir (Ro 31 -8959, Invirase®) was the first mem­
ber of its class to be approved in 1995 in the USA by 
the FDA under its accelerated approval regulations for 
use in combination with approved nucleoside reverse 
transcriptase inhibitors in patients with advanced HIV 
infection. Saquinavir is marketed by Roche. 
Saquinavir has been approved in the European 
Community in October 1996. Saquinavir (Figure 2) is 
a peptide derivative, which is a transition-state 
mimetic of the Phe-Pro peptide bond.
Efficacy of saquinavir monotherapy
Dosages of saquinavir ranging from 25 to 600 mg tid 
were investigated in two randomised, double-blind 
phase I/ll studies, The 013328 study was performed 
during 16 weeks in 49 antiretroviral naive patients 
with CD4+ lymphocyte counts <500 cells/jwL [17]. 
Effects on CD4+ lymphocyte counts and HIV RNA load 
are summarized in Table 1. The highest dose group 
showed the largest increase in CD4+ lymphocytes and 
the largest reduction in HIV RNA load.
The V I3329 study was performed in 45 zidovu-
Figure 2
Molecular structure of saquinavir (Invirase®).
dine-experienced patients with CD4+ lymphocyte 
counts ranging from 50-250 cells/p/L (Table 1). The 
highest dose regimen (600 mg ticf) was the most 
effective in terms of increase in CD4+ lymphocytes 
and decrease in HIV RNA load [18],
A third study compared high dosages of saquinavir 
monotherapy 3600 and 7200 mg/day, during 24 
weeks [19]. Patients had CD4+ lymphocyte counts 
ranging from 200-500 ceils/juL (Table 1). The high- 
dose regimen produced a greater reduction in plasma 
HIV RNA and PBMC HIV cultures, and a greater 
increase in CD4+ lymphocytes.
Thus, these studies with saquinavir monotherapy 
showed greater and more sustained efficacy with 
higher dosages* The maximum decrease in HIV RNA 
load with saquinavir monotherapy in currently rec­
ommended doses (600 mg tid) is comparable to that 
seen with monotherapy with nucleoside reverse tran­
scriptase inhibitors. Saquinavir monotherapy does not 
lead to a sustained decline in HIV RNA load and 
increase in CD4+ lymphocytes.
Efficacy of saquinavir in combination therapy
In several clinical studies the antiviral effect of saqui­
navir in combination therapy has been investigated 
(Table 2). In a double-blind, randomised trial (ACTG 
229), triple therapy (saquinavir/zidovudine/zalcita- 
bine) was compared with two double therapies 
(saquinavir/zidovudine, and zidovudine/zalcitabine) 
in 297 zidovudine-experienced patients with CD4+ 
lymphocyte counts ranging from 50-300 cells/p/L
[20], The median increase in CD4+ lymphocyte count 
at week 24 and 48 was higher in the triple therapy 
group (Table 2). Suppression of HIV in cultures of 
PBMCs and of HIV RNA load was also greater and 
more sustained in the triple therapy group,
The V I3330 study compared saquinavir and zidov­
udine monotherapy with combination therapy of 
saquinavir/zidovudine in 71 previously untreated 
patients with CD4+ lymphocyte counts <300 cells/^L
[21]. Patients received saquinavir monotherapy 600 
mg tid, zidovudine monotherapy 200 mg tid, saqui­
navir 75 mg tid plus zidovudine 200 mg tid, saquina-
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Table 2 Effects of saquinavir in combination with nucleoside analogues on CD4+ lymphocyte counts and HIV RNA load
Reference change in CD/  lymphocyte counts 
from baseline (cells/jjl)
change in HIV RNA load 
(]0log units) from baseline
drag regimen 
(mgtid)
patients (N) change at week
4 8 16 24 48
change at week 
4 8 12 16 20 24
20 SAQ 600+AZT 200+DDC 0.75
(ACTC 229) 5AQ 600+AZT 200 
AZT 200+DDC 0.75
21 SAQ 600
(V13330) AZT 200
SAQ 75+AZT 200 
SAQ 200+AZT 200 
SAQ 600+AZT 200
22,23 SAQ 600+DDC 0.75
(NV14256) SAQ 600 
DDC 0.75
24 SAQ 600+AZT 200+3TC150b
25 SAQ 600+D4T 40b
26 SAQ400b+RlT400b 
SAQ 400b+RIT 600b 
SAQ 400 +RIT400 
SAQ 600b+RlT 600b
27 SAQ600b+RlT600b
98 +31 +22
99 +18 +5 
100 +6 +3
15 +33
13 +22
14 +21
14 +34
15 +50
308 +26a
318 +10a
314 +3a
33 +108
14 +32 +57 
140
7 +39 +59
-1.09
-Q,6a 
-0.1a 
~0.3a
‘1.96
-1,6 -0,9
-3.21
-3.17
-2,68
-2.73
-1.44 -1.03
a determined in a subset of 451 patients [23]
*bid
c total of both study arms 
d mean of both study arms
Abbreviations: 3TC = lamivudine, AZT = zidovudine, D4T = stavudine, DDC - zalcitabine, RiT = ritonavir, SAQ = saquinavir.
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vir 200 mg tid plus zidovudine 200 mg tidt or saqui­
navir 600 mg tid plus zidovudine 200 mg tid. The 
greatest increase in CD4+ lymphocyte count was 
observed in patients who used saquinavir 600 mg tid 
plus zidovudine 200 mg tid (Table 2). Furthermore, 
the largest reduction in HIV RNA load (1.6 10log units 
at week 2) was also observed in this arm.
The NV14256 trial compared the combination 
therapy saquinavir/zalcitabine with saquinavir and 
zalcitabine monotherapies in 940 patients with CD4+ 
lymphocyte counts between 50-300 ceWs/pl, and 
who had received zidovudine for at least 16 weeks 
[22]. Treatment with the combination of saquina­
vir/zalcitabine significantly increased the time to the 
first AIDS-defining event and death, or death alone
compared with zalcitabine monotherapy. The relative 
risk of developing a first AIDS-defining event or death 
in the combination group was 0.47 (95% confidence 
interval 0,33 to 0.67) compared to zalcitabine mono­
therapy; the relative risk of death was 0.28 (95% con- tion (200 copies/mL). 
fidence interval 0.13 to 0.60) in favour of the combi-
[23]. The combination therapy was associated with a 
greater increase in CD4+ lymphocyte count and a 
greater reduction in HIV RNA load compared with the 
monotherapy arms (Table 2). The difference in CD4+ 
lymphocyte count was not statistically significant 
between the two monotherapy arms, although the 
reduction in HIV RNA load was higher in the zalcita­
bine monotherapy arm compared to the saquinavir 
monotherapy arm.
An exploratory, single arm, open-label study of 
combination therapy with saquinavir (600 mg tid) 
plus lamivudine (150 mg bid) plus zidovudine (200 
mg tid) has been conducted [24]. 33 HIV infected, 
antiretroviral naive patients with CD4+ lymphocyte 
counts ranging from 150-500 cells/pL were included 
(Table 2). The peak increase in CD4+ lymphocyte 
count was 153 cells/pL; the peak decline in HIV RNA 
load was 2.10 10log units. After week 4, 34% of the 
patients had HIV RNA load below the limit of detec-
162
nation therapy. No differences in morbidity or mortal­
ity were observed between the monotherapy arms. In 
a subset of 451 patients changes in CD4+ lympho­
cytes and HIV RNA at week 16 have been presented
Saquinavir (600 mg tid) was added to 14 patients 
with advanced HIV infection who were previously 
treated with stavudine (40 mg bid) [25], A decrease in 
HIV RNA load of 1.6 10log units was observed at week 
4; after 8 weeks a decrease of 0.9 10log units was
reported. The increase in CD4+ lymphocyte count was 
32 cells/jjL at week 4, and 57 at week 8, However, the 
changes in CD4+ lymphocytes were not statistically
significant.
Combination therapy of saquinavir and ritonavir were reversible [19].
(most commonly gastrointestinal problems and ele­
vated serum aminotransferase levels) were more com­
mon in patients receiving the highest dose regimen, 
but most adverse effects were mild, tolerable and all
(see further) has been elaborated. Rationales for com­
bining these protease inhibitors are: both drugs dem­
onstrated improvement in survival and disease pro­
gression in large clinical trials, they show divergent 
resistance patterns, and ritonavir enhances and sus­
tains saquinavir plasma concentrations.
In a randomized, open-label study the efficacy of 
the combination of saquinavir and ritonavir in four 
dose schedules was investigated in 140 patients with 
CD4+ lymphocyte counts between 100-500 cells/pL
[26]. Administration of reverse transcriptase inhibitors 
was stopped. Preliminary data up to 20 weeks of ther­
apy have been presented [26]. Combination therapy 
shows a strong decline in HIV RNA load (Table 2).
In a pilot study the combination of saquinavir and 
ritonavir was studied in 7 patients with advanced HIV 
disease (median CD4+ lymphocyte count 10 cells/p/L)
[27]. From day 1 to 7 patients were treated with 
ritonavir 600 mg bid. From day 8 to 14 saquinavir 200 
mg bid was added, and increased to 600 mg bid after 
day 15. After 4 weeks of combination therapy, the 
decrease in HIV RNA load was 1.44 10log units, and
1.03 10log units after 8 weeks of combination thera­
py. CD4+ lymphocyte counts increased 39 cells/f/L 
after 4 weeks, and 59 cells/^L after 8 weeks of combi­
nation therapy, respectively (Table 2).
The comparative trials indicate that saquinavir is 
more effective when administered in combination 
with nucleoside reverse transcriptase inhibitors com­
pared to monotherapy. Furthermore, the decline in 
HIV RNA load ranges from approximately 1 to 2 10log 
units when saquinavir is combined with stavudine, 
ritonavir, or zidovudine plus lamivudine. The duration 
of response in combination therapy regimens appears 
also to be more sustained. In conclusion, the efficacy 
of saquinavir is larger in combination therapy regi­
mens compared to monotherapy.
Saquinavir in primary HIV infection
Three patients were treated with saquinavir (7200 
mg/day), zidovudine (500 mg/day), and lamivudine 
(600 mg/day) after primary infection with HIV [28]. 
Pretreatment HIV RNA loads were 6.5, 4.4, and 4.0 
10log units. HIV RNA load fell below the limit of detec­
tion (200 copies/mL) after 15, 3.5, and 2 weeks, 
respectively. Duration of treatment for at least 5, 1.5, 
and 0.5 months, respectively, still shows HIV RNA 
load below the limit of detection with no signs of clin­
ical progression. Treatment was well tolerated and 
required no drug discontinuation.
Adverse effects
In general, saquinavir is well tolerated. In the large 
NV14256 trial the most common adverse effects of 
saquinavir given in a dose of 1,800 mg/day included 
diarrhoea, abdominal discomfort, and nausea [18]. 
Diarrhoea was the most common single adverse 
event occurring in 3.8% of all patients. The most 
common laboratory abnormality was the increase in 
creatine phosphokinase level in 4% of the patients.
In a study with high dosages of saquinavir mono­
therapy (3600 and 7200 mg/day), adverse reactions
In the ACTG 229 study (comparing saquina- 
vir/zidovudine/zalcitabine, saquinavir/zidovudine, 
and zidovudine/zalcitabine) no differences in adverse 
effects or laboratory abnormalities were reported for 
the treatment groups [20]. The combination of saqui­
navir plus ritonavir is also well tolerated [26 27],
Resistance to saquinavir
In vitro studies have revealed saquinavir-resistant HIV 
strains, with IC90 values up to more than 50 times 
those for wild-type HIV [29-34]. Two common muta­
tions are found: the C48V, and the L90M mutation 
[31 32 34-36]. The C48V mutation is the first to 
appear in vitro [35], Recently, the in vitro susceptibility 
of various HIV-1 clinical isolates for the combination 
of saquinavir and indinavir was determined [37]. 
Against a pan-susceptible clinical isolate the interac­
tive effects of saquinavir and indinavir ranged from 
synergistic at low doses to antagonistic at high doses. 
Against a zidovudine-resistant strain the combination 
showed antagonism at all doses. The clinical conse­
quences of these in vitro observations is not clear yet. 
Significant cross-resistance between saquinavir and 
other protease inhibitors has not been observed in 
vitro so far [18 36 38].
The C48V and L90M mutations have been detect­
ed in viral isolates from patients treated with saquina­
vir monotherapy, with the L90M mutation being 
most frequently observed (up to 45%) [18]. The fre­
quency of this mutation in patients who also used 
zidovudine and zalcitabine was lower. The mutations 
were not observed in virus from untreated patients. 
The presence of both mutations was detected in 
2.4% of the patients using saquinavir monotherapy 
[36]. Patients treated with higher dosages of saquina­
vir (up to 7200 mg/day) showed lower frequencies of 
saquinavir-resistant mutations [19 36]. In general, 
genotypic and phenotypic resistance to saquinavir 
appears to develop relatively slow. High dose therapy 
with saquinavir or combination therapy with nucle­
oside analogues appears to reduce the risk of the 
development of resistant virus. Cross-resistance with 
other protease inhibitors in vivo has been reported, 
but its incidence appears to be low [18 39 40].
Dosage and administration
The formal dosage of saquinavir is 600 mg tid in com­
bination with nucleoside analogues. However, in 
some countries a dosage of 1200 mg tid is now com­
mon practice. Saquinavir should be taken within 2 
hours of a meal [18]. Saquinavir (as mesylate) is avail­
able as 200 mg capsules. A new formulation of saqui­
navir is in development (soft gelatin capsule) and is 
expected to increase oral availability from 4 to 12%. A 
formulation for paediatric use is also being developed 
[18].
Pharmacokinetics
As a result of limited absorption and extensive first- 
pass metabolism the bioavailability of a single 600 mg 
oral saquinavir dose taken with food is 4%. In the fast­
ing state the bioavailability is 18 times lower [18 41 ].
In healthy volunteers the maximum plasma concen­
tration (Cmax) after a single 600 mg oral dose taken 
with food is 66.1 ng/mL [18 41 42], After multiple 
doses the Cmax was 90.4 ng/mL [18], Time to Cmax 
(Tmax) is 3-4 hours after administration of saquinavir 
capsules with food [18 41]. Administration of saqui­
navir suspension in a fasted state yielded a Tmax value 
of 0.77 hours [43]. Steady-state plasma concentra­
tions of saquinavir in HIV infected patients appear to 
be higher than in healthy volunteers with a Cmax of
242.3 ng/mL after multiple oral doses of 600 mg 
[18]. A 1 -hour infusion of 12 mg saquinavir in healthy 
volunteers yielded a steady-state volume of distribu­
tion of 703 L, thus suggesting extensive tissue bind­
ing. Saquinavir is highly bound to plasma proteins 
(>98%) [16]. The value for total plasma clearance was 
98.8 L/h, and the terminal plasma half-life was 13.2 h 
[41], Elimination of saquinavir is predominantly non- 
renal; after a 600 mg oral dose 88% was detected in 
the faeces, whilst 1% was excreted in the urine [18]. 
Saquinavir pharmacokinetics appear to be non-linear, 
with higher dosages leading to a more than propor­
tional increase in the area under the concentration 
versus time curve (AUC) and Cmax [18]. Saquinavir is 
rapidly metabolised by the cytochrome P450-3A4 iso­
enzyme to a number of inactive mono- and dihydrox- 
ylated metabolites [18 44].
The pharmacokinetics of saquinavir in HIV infected 
patients with severe diarrhoea or wasting syndrome 
have been investigated [45]. Preliminary results indi­
cate that plasma concentrations of saquinavir are at 
least equal to those achieved in healthy volunteers. 
Saquinavir pharmacokinetics have not been studied 
in patients with hepatic or renal insufficiency.
Pharmacokinetic-pharmacodynamic relationships
In contrast to nucleoside reverse transcriptase inhibi­
tors, pharmacokinetic-pharmacodynamic relation­
ships are more easily found with protease inhibitors. 
Most likely this can be explained by the need for 
intracellular phosphorylation to the active triphos­
phate anabolites in case of the nucleoside analogues. 
In the Ol 3328 study, a positive linear relationship was 
found between saquinavir AUC and the change in 
CD4+ lymphocytes after 2 weeks of treatment [17]. In 
a 24~week study, two high doses of saquinavir mono­
therapy (3600 and 7200 mg/day) were compared in 
40 HIV infected patients. In a subset of 16 patients the 
pharmacokinetics of saquinavir were studied and a 
strong correlation between saquinavir AUC and 
decrease in viral load at week 4 was observed in both 
arms [19],
A linear relationship between AUC and the change 
in CD4+ lymphocyte count is predicted over the dose 
range 75-600 mg tid from a model based on data 
from 61 patients with advanced HIV disease who 
were treated with saquinavir for 16 weeks. An AUC0_8 
hours value of 700 /vg/L*h was predictive of a peak 
increase in CD4+ lymphocytes of 26 cells/^L on day 
19, and of CD4+ lymphocytes remaining above base­
line during 16 weeks of treatment [18].
Thus, though limited data on saquinavir pharma­
cokinetics and efficacy are available, relationships 
have been found between saquinavir pharmacokinet­
ics (AUC) and efficacy in terms of decrease in HIV RNA 
load and increase in CD4+ lymphocytes. Regarding 
the low and variable bioavailabiiity of saquinavir [41],
max of saquinavir with 40% [46], The maximum
monitoring drug concentrations in patients to ensure 
drug efficacy and to prevent the risk of drug resis­
tance, appears to be warranted.
Drug interactions
Co-administration of rifampin 600 mg/day and saqui­
navir 600 mg tid decreased the steady-state AUC and 
Cmax values of saquinavir with 80% in healthy volun­
teers [18]. Co-administration of rifabutin 300 mg/day 
and saquinavir 600 mg tid decreased the AUC and 
C
effect had been reached after 1 week. Presumably, 
these important observations are caused by the 
induction of cytochrome P450 enzymes by rifampin 
and rifabutin. Concomitant administration of saqui­
navir and drugs that are metabolised by cytochrome 
P450-3A4 isoenzymes may result in increased plasma 
concentrations of the latter drugs. Therefore, it is 
advised not to prescribe astemizole and terfenadine 
to patients who use saquinavir, since this combination 
may lead to an increased risk of cardiac arrhythmia 
[18], The AUC and Cmax of saquinavir were increased 
three-fold when saquinavir (600 mg tid) was com­
bined with ketoconazole 200 mg/day in healthy vol­
unteers in a multiple-dose study [18]. Single-dose 
administration of saquinavir plus ranitidine increased 
the bioavailability of saquinavir by 67% [18].
Co-administration of saquinavir with ritonavir 
increased the AUC and Cmax of saquinavir by >290- 
and 18-fold in rats, respectively [47], Co-administra­
tion of saquinavir and ritonavir in healthy volunteers 
also revealed an increase in saquinavir exposure [48]. 
The pharmacokinetics of saquinavir and ritonavir 
were investigated after single- and multiple-dose 
administration in several regimens. The single-dose 
study revealed that combining saquinavir 600 mg 
and ritonavir 600 mg increased saquinavir Cmax val­
ues nearly 30-fold; saquinavir AUC values increased 
90-fold. Ritonavir pharmacokinetics were not affect­
ed. The multiple-dose study showed similar results.
Combination of saquinavir 600 mg tid and ritonavir 
300 mg bid showed a 16-fold increase in saquinavir 
Cmax anc ^a 21 -fold increase in AUC [49],
Plasma concentrations of saquinavir may be 
decreased if phénobarbital, phenytoin, dexametha- 
sone, or carbamazepine are co-administered, 
although no data are currently available from studies. 
Concurrent administration of saquinavir and cisa­
pride, calcium-channel blocking agents, clindamycin, 
dapsone, quinidine, triazolam, or midazolam may 
theoretically lead to increased concentrations of the 
co-administered drugs due to inhibition of their 
metabolism [50].
Figure 3
Molecular structure of indinavir (Crixivan®).
Table 3 Effects of indinavir monotherapy on CD4+ lymphocyte counts and HIV RNA load
Reference change in CD/ lymphocyte count from baseline change In HIV RNA load from baseline
(cells/yL) (10log units)
dose patients (N) change at week 
8 12 14 24 36 48
change at week 
6 8 24 48
57 1.6-1.8 g/day 38 +89 +82 +72 -0.3 -0.3
16 600 mg qid 16 +104 +105 +126 -1.98
59
»
2.4 g/day 
3.0 g/day 
3.2 g/day
70a +80
to
+145b
+85 -2.3
to
-2.6b
-2.63
56 600 mg qid 5 +143 -1.55 -0.64
a total of three study arms 
b not specified
Indinavir
Indinavir (L-735,524, MK-639, Crixivan®, Figure 3) is 
marketed by Merck. In the USA indinavir is approved 
by the FDA under its accelerated approval regulations 
for use as monotherapy or in combination with 
approved nucleoside analogues in patients with HIV 
infection. Indinavir has been approved in the 
European Community in October 1996.
Initially starting from a peptide renin lead com­
pound, a series of hydroxyethylene dipeptide inhibi­
tors of HIV protease were developed [51 52], Though 
highly potent, these compounds lack aqueous solubil­
ity and desirable pharmacokinetic properties. The 
incorporation of an amine resulted in hydroxyamino- 
pentane amides, in which potent antiviral activity and 
acceptable bioavailability are combined [53 54].
Efficacy of indinavir monotherapy
Results from phase l/II trials in zidovudine-experi­
enced patients with <500 CD4+ lymphocytes//jL and 
>25 pg/mL of p24 antigen have been presented [57]. 
Doses of indinavir ranging from 1.6 to 1.8 g/day 
resulted in an initial decline in HIV RNA load of 1.1 
10log units (Table 3).
In a double-blind phase II trial in 74 patients with 
£500 CD4+ lymphocytes/^L, indinavir at two dose lev­
els (200 or 400 mg qid) was compared with zidovu­
dine monotherapy (200 mg ticf) [58]. Increases in 
CD4+ lymphocytes and decreases in HIV RNA load 
and p24 antigen levels were observed. The largest 
initial decrease in HIV RNA load was observed in the 
highest indinavir dose group (> 1 10log reduction). 
HIV RNA load returned to baseline between 12 and 
24 weeks and viral resistance developed. After 24
In one study high doses of indinavir monotherapy 
were compared with respect to increase in CD4+ lym­
phocyte cell count and decrease in viral load [59], A 
total of 70 patients with a median entry CD4+ lym­
phocyte cell count of 250 cells/juL and a median plas­
ma HIV RNA load of 70,795 copies/mL were included 
(Table 3). No differences between the treatment arms 
were observed in immunological or viral markers of 
disease progression. At week 24 approximately 40% 
of all patients had plasma HIV RNA levels below the 
limit of detection (200 copies/mL). After 48 weeks of 
treatment with 2,400 mg/day 54% of the patients 
had plasma HIV RNA levels below the limit of detec­
tion. No differences were observed at this time point, 
nor compared to the higher dose groups, nor com­
pared to the results at week 24.
An open-label, 24-week phase I/ll study was con­
ducted in 5 patients with CD4+ lymphocyte counts 
<300 cells/^ /L, and >20,000 HIV RNA copies/mL [56]. 
Patients were extensively pretreated with nucleoside 
analogues and received indinavir 600 mg qid. Effects 
on HIV RNA load and CD4+ lymphocytes are summar­
ised in Table 3.
The safety and efficacy of indinavir has also been 
investigated in HIV infected children. A phase I/ll 
study in 26 HIV infected children with indinavir 
monotherapy has been presented [60]. Patients were 
divided into two groups according to their age (<12 
or > 12 years). Three dose groups were created: 250, 
350, and 500 mg/m2 tid. Formulations of indinavir 
used were a suspension and capsules. After 12 weeks 
of therapy the suspension was replaced by capsules at 
a fixed dose of 250 mg/m2 tid; 5 children used cap­
sules throughout the study. Zidovudine plus lamivu-
weeks of therapy the indinavir dosage was increased dine were added to the regimen after week 16. The
to 600 mg qid. After 52 weeks of therapy CD4+ lym­
phocytes remained above baseline in patients treated 
with indinavir. No further decrease in HIV RNA load, 
however, was observed after dose escalation.
An open-label monotherapy study at a dosage of 
600 mg qid in 16 zidovudine-experienced patients 
with CD4+ lymphocyte cell counts <500 ceWs/pl 
resulted in significant declines in HIV RNA load and 
increases in CD4+ lymphocytes (Table 3) [16].
median increase in CD4+ lymphocytes in the 250 and 
350 mg/m2 tid dose groups at week 16 was 99 
cells/juL. HIV RNA levels in patients receiving indinavir 
suspension in the two lowest dose groups showed a 
median maximum decrease of 0.7 10log units.
In contrast to saquinavir, no larger antiretroviral 
efficacy of indinavir (measured as virological or immu­
nological response) was obtained with higher dosag­
es than currently recommended, e.g. 800 mg tid
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Table 4 Effects of indinavir in combination with nucleoside analogues on CD4+ lymphocyte counts and HIV RNA load.
Reference change in CD/ lymphocyte change in HiV RNA patients with HIV
counts from baseline load (] °log units) RNA below detection
(cells/pL) from baseline limit (%)
drug regimen 
(mg tid)
change at week 
24 44
change at week 
24 44
week
24 32 44
63 iDV 600 qid+AZT 200 -2.5
IDV 600 qid -1.5
AZT 200 -0.3
62 IDV 800+AZT 200+3TC 150a +126 +218 -2.2 -2.2 92 83 83
(protocol 035) IDV 800 +105 +158 -0.7 -0.9 38 36 22
AZT 2Ü0+3TC 150a +14 +14 -0.6 -0,2 0 0 0
64 (DV 800+AZT 200 +121 -1.09 36
(protocol 028) IDV 800 +125 -0.86 37
AZT 200 +16 -0.27 7
65 IDV 800+AZT 200 +95 -1,19 56
(protocol 033) IDV 800 +109 -1.03 37
AZT 200 +14 -0.26 2
a 3TC was administered twice daily,
Abbreviations: 3TC =* lamivudine, AZT = zidovudine, IDV = indinavir.
2'¡3
[59]. The maximal decline in HiV RNA load observed 
with indinavir monotherapy in currently recommend­
ed doses (2.4 g/day) is generally more than 2 10fog
regimen with respect to the decrease in HIV RNA load 
(maximum -2.2 10log units at 24 weeks), increase in 
CD4+ lymphocytes (maximum +218 at 44 weeks),
units. This indicates that indinavir monotherapy may 
result in larger and more sustained suppression of 
viral load compared to monotherapy with either week 24). 
saquinavir or reverse transcriptase inhibitors,
and the percentage of patients with HIV RNA load 
below the detection limit, 500 copies/mL (92% at
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Efficacy of indinavir in combination therapy
A summary of three phase II trials with indinavir has 
recently been presented [61]. In two studies, patients 
were randomised to indinavir monotherapy (800 mg 
tid, n=67), zidovudine or zidovudine plus didanosine 
(n=47), or indinavir plus a reverse transcriptase inhibi­
tor (n=53). After week 24 the median increase in 
CD4+ lymphocytes ranged from 26-80 cells/pL in the 
indinavir monotherapy arms. The median maximal 
decline in viral load ranged from 2.0 to 2.3 10tog units 
in this group; 9 to 40% of these patients had plasma 
HIV RNA levels below the limit of detection (200 cop- 
ies/mL). The changes in viral load and CD4+ lympho­
cyte counts were not different in patients receiving 
combination therapy with indinavir plus a nucleoside 
analogue, though the percentage of patients with 
viral load below the limit of detection tended to be 
greater in the combination therapy arm.
In a randomized, double-blind study indinavir 
monotherapy was compared with combination thera­
py of zidovudine/lamivudine, and ind'rnavir/zidovu- 
dine/lamivudine in 97 HIV-infected patients (protocol 
035) [62]. Patients had 50-400 CD4+ lymphocyte 
ce\\s/fjL and >20,000 copies of HIV RNA/mL, and had 
received >6 months of zidovudine therapy. Results of 
the effects on HIV RNA load and CD/- lymphocyte 
counts up to week 44 have been presented (Table 4). 
The triple combination therapy was the most effective
Preliminary results of a double-blind, randomised 
trial of indinavir monotherapy, zidovudine monother­
apy, and indinavir/zidovudine combination therapy in 
73 zidovudine-naive patients with CD4+ lymphocyte 
cell counts <500 cells//7L and a HIV RNA load >20,000 
copies/mL have been presented (Table 4) [63]. The 
maximal decrease in HIV RNA load was -2.6, -2.3, and 
-0.6 10fog units for the combination, the indinavir 
monotherapy, and the zidovudine monotherapy 
arms, respectively. The indinavir-containing arms 
showed increases of 50 CD4+ lymphocyte cells/pl 
compared to the zidovudine monotherapy arm after 
24 weeks of therapy. The results on HIV RNA load 
indicate that the addition of zidovudine to indinavir 
does not have a profound effect on the initial 
decrease in HIV RNA load, but that the effect might 
be more sustained.
In a double-blind, randomized trial (protocol 028), 
indinavir monotherapy was compared with zidovu­
dine monotherapy, and combination therapy of 
indinavir/zidovudine in 224 patients with CD4+ lym­
phocyte counts ranging from 50-250 cells/pL (Table 
4) [64]. Results up to week 24 revealed a larger 
increase in CD4+ lymphocytes, and a larger decrease 
in HIV RNA load in the indinavir containing arms. No 
differences between the indinavir monotherapy arm 
and the combination arm were detected. In the indin­
avir-containing arms the percentages of patients with 
undetectable HIV RNA load were higher than in the 
zidovudine monotherapy group.
A double-blind, randomized trial (protocol 033)
was conducted in 266 patients with CD4* lymphocyte 
counts ranging from 50-500 cells//A, who were naive 
to zidovudine and protease inhibitors. Indinavir 
monotherapy was compared with zidovudine mono­
therapy, and combination therapy of indinavir/zidov­
udine (Table 4) [65]. Results up to week 24 reveal a 
larger increase in CD4+ lymphocytes, and larger 
decrease in HIV RNA load in the indinavir-containing 
arms. No differences between the indinavir mono­
therapy arm and the combination arm were detected. 
The percentages of patients with undetectable HIV 
RNA load were higher in the indinavir-containing 
arms than in the zidovudine monotherapy arm.
An interim analysis of protocols 028 and 033 in 
490 patients showed that addition of zidovudine to 
indinavir therapy causes no additional benefit on 
CD4+ lymphocyte cell count, but adds small, though 
statistically significant effect on the decrease in HIV 
RNA load, especially in patients with high baseline 
viral load [66].
A pilot study was conducted to investigate the 
effect of indinavir monotherapy with intermittent 
interleukin-2 in HIV-infected patients with CD4+ lym­
phocyte cell counts <300 cells/juL [67 68]. Three 
treatment arms were created: in the first arm patients 
received interleukin-2 for 5 days every 2 months in a 
dose of >12 MlU/day plus indinavir 600 mg qid (A). In 
the second arm patients received indinavir 600 mg 
qid for 10 days during a similar interleukin-2 cycle (B), 
and in the third arm patients received indinavir 
monotherapy 600 mg qid (C). After 14 weeks the fol­
lowing results were obtained. In the first group the 
increase in CD4+ lymphocyte count was 196 cells/jwL, 
and the increase in HIV RNA load was 0.03 10log 
units. In the second group the increase in CD4+ lym­
phocyte count was 85 cells//vL, and the HIV RNA load 
increased with 0.4 10log units. In the third group the 
CD4+ lymphocyte count increased with 113 cells/jwL, 
while the HIV RNA load decreased with 0.57 10log 
units. These results indicate that the combination of 
indinavir and interleukin-2 leads to increases in CD4+ 
lymphocyte cell count, but does not lead to changes 
in HIV RNA load.
Phase III protocols are currently underway. ACTG 
320 will be a randomized, double-blind study of 
indinavir with open-label zidovudine and lamivudine 
in patients with <200 CD4+ lymphocytes//;!.. Disease 
progression and death are the primary endpoints of 
this study.
Adverse effects
Adverse effects of indinavir include nephrolithiasis in 
up to 5% of the patients [16]. The frequency of neph­
rolithiasis increases with doses exceeding 2.4 g/day. 
Nephrolithiasis may be caused by crystallisation of 
indinavir in the urine. Therefore, it is recommended 
that patients drink at least 1.5 L of fluid extra per day. 
Furthermore, asymptomatic hyperbilirubinaemia (pri­
marily as elevated indirect bilirubin) is reported in up 
to 15% of the patients.
Resistance to indinavir
The in vitro susceptibility of HIV-1 clinical isolates for 
the combination of saquinavir and indinavir has been 
described before [37]. Complete in vitro cross-resis­
tance between indinavir and ritonavir has been 
reported [69]. Approximately two-thirds of indinavir
resistant viral strains studied by Merck are cross-resist­
ant to saquinavir, but all saquinavir-resistant strains 
studied thus far are (at least initially) fully sensitive to 
indinavir [69].
In protocol 019 patients were treated with indina­
vir monotherapy, zidovudine monotherapy, or combi­
nation therapy with indinavir/zidovudine. The emer­
gence of resistance to indinavir was reduced (but not 
significant) in patients treated with the combination 
therapy compared to the indinavir monotherapy arm 
[70]. The resistance to zidovudine was significantly 
reduced in patients receiving indinavir plus zidovu­
dine compared to zidovudine monotherapy.
In protocol 020, patients received either a combi­
nation of indinavir/zidovudine/didanosine, orzidovu- 
dine/didanosine, or indinavir monotherapy [70]. A 
highly significant reduction in indinavir resistance was 
observed in patients receiving the triple combination. 
Similarly, a significant reduction in resistance to zidov­
udine or didanosine was observed in patients of this 
group.
Dosage and administration
The currently recommended dosage of indinavir is 
800 mg tid, either alone or in combination with 
nucleoside analogues. Indinavir should be taken with 
a tight meal or on an empty stomach (one hour 
before, or two hours after a meal). Indinavir (as the 
sulphate) is available as 200 and 400 mg capsules. It 
is recommended to reduce the dosage of indinavir to 
600 mg tid in patients with liver insufficiency and in 
patients with repeated nephrolithiasis despite ade­
quate intake of fluids [71 ].
Pharmacokinetics
The pharmacokinetics of indinavir were investigated 
in asymptomatic patients at 100, 200, and 400 mg 
qid in a multiple dose study [72]. The mean Tmax was 
<1 hour and the plasma elimination half-life was 1-2 
hours. After 10 days of administration the plasma 
Cmax exceeded the target concentration of 100 nM in 
the highest dose group (the 1C95 for virus inhibition is 
<100 nM). The plasma trough concentration was 199 
± 139 nM.
Indinavir pharmacokinetics were studied in HIV 
negative persons after a single gift in the dose range 
from 20-1,000 mg [73]. The Tniax was <1 hour, and 
the plasma half-life was 1 -2 hours. The sulphate salt of 
indinavir resulted in smaller inter-subject variability 
compared to the base. The AUC of indinavir was 70 to 
80% lower if 400 mg was administered with a meal 
compared to fasted administration. In single- and 
multiple-dose studies the AUC increased dispropor- 
tional with dose. Little accumulation in plasma 
occurred following multiple doses (< 30% increase in 
AUC).
At a dosing regimen of 800 mg tid AUC values 
were 30,691 ± 11,407 nM*h, Cma>< values reached 
12,617 ± 4,037 nM, and the plasma trough concen­
tration was 251 ± 1 78 nM [74],
The plasma protein binding of 60% is relatively low 
compared to saquinavir and ritonavir [56]. Indinavir 
might benefit from lower plasma protein binding; this 
may result in more substantial penetration into cere­
brospinal fluid, or in higher tissue concentrations 
[16].
Seven metabolites of indinavir have been detected
in the urine of healthy volunteers [55]. The cyto­
chrome P450-3A4 appears to be the major enzyme 
responsible for formation of metabolites. The metab­
olites comprised <0.5% of the dose in the first four 
hours after administration. The cumulative amount of 
unchanged indinavir in the urine is approximately 
12% of the administered dose.
Patients with mild to moderate hepatic insufficien­
cy and clinical evidence of cirrhosis showed a 
decrease in indinavir metabolism resulting in 60% 
higher AÜC values after a single 400 mg dose [74]. 
The half-life of indinavir increased to 2.8 h. Indinavir 
pharmacokinetics have not been studied In patients 
with severe hepatic or renal insufficiency. Indinavir 
pharmacokinetics appear to be comparable in men 
and women, and in Caucasians and Blacks [74].
Pharmacokinetic-pharmacodynamic relationships
In an open-label phase I/II study in 5 HIV-infected 
men the relationship between indinavir pharmacoki­
netics and pharmacodynamics was studied [56], 
Indinavir was administered as a monotherapy regi­
men. No relationship was found between C ^  and 
the decrease in viral load. However, a positive rela­
tionship was found between indinavir AUC and the 
reduction in virai load. Furthermore, a positive rela­
tionship was found between indinavir trough plasma 
concentration (Cmln) and the reduction in viral load. 
The relationships between AUC or Cmin and the 
decrease in virai load is extremely steep. Thus, the 
possibility of monitoring indinavir concentrations to 
ensure sufficient exposure should be investigated.
Drug Interactions
Pharmacokinetic drug-drug interactions with indina­
vir are anticipated for drugs that are substrates for 
cytochrome P450-3A enzymes. Pharmacokinetic 
interaction studies have been conducted in HIV 
infected patients [75]. The effect of trimethoprim, sul­
famethoxazole, zidovudine, stavudine, Isoniazid, cla­
rithromycin, rifabutin, and fluconazole on indinavir 
AUC, and the effect of indinavir on the AUC of these 
drugs has been investigated. No clinically significant 
interaction occurred with trimethoprim, sulfamethox­
azole, zidovudine, stavudine, isoniazide, and flucona­
zole. The plasma concentrations of clarithromycin 
and rifabutin, however, increased after co-administra­
tion with indinavir; the interaction with rifabutin was 
considered to be clinically significant. The rifabutin 
plasma AUC and Cmax increased with 173 and 1 35%, 
respectively. Rifabutin decreased the plasma AUC and 
Cmax of indinavir with 34 and 25%, respectively. 
Therefore, a dose adjustment to half the standard 
dose of rifabutin is recommended if coadministered 
with indinavir [71 75].
The absence of a clinically significant pharmacoki­
netic interaction between indinavir and fluconazole 
was confirmed in 13 patients [76]. In this study an 
unexpected, significant decrease (24%) in indinavir 
plasma AUC was observed if fluconazole was co­
administered.
Concurrent administration of ketoconazole 400 mg 
plus indinavir400 mg resulted in an increase in indin­
avir AUC and Cmax of 62 and 14%, respectively. 
Therefore, it is recommended to reduce the dose of 
indinavir to 600 mg tid if coadministered with keto­
conazole [71].
No pharmacokinetic Interaction study with rifam­
pin has been performed yet. Since rifampin is a strong 
inducer of cytochrome P450-3A4 enzymes it is antici­
pated that concurrent administration of indinavir and 
rifampin may lead to decreased indinavir concentra­
tions.
Other drugs that induce cytochrome P450-3A4 
enzymes include phénobarbital, phenytoin, dexa- 
methasone, and carbamazepine. Concurrent adminis- 
tration of one of these drugs and Indinavir may lead 
to decreased indinavir concentrations [71].
Coadministration of indinavir and itraconazole may 
lead to increased indinavir concentrations due to the 
inhibitory effect of itraconazole on the cytochrome 
P450-3A4 enzyme. This potential interaction has, 
however, not been investigated yet.
Up to now no study has been performed in which 
the effect of concurrently administered didanosine on 
indinavir absorption is investigated. Since didanosine 
Is an acid-labile compound, Its formulation contains 
compounds to Increase gastric pH. Adequate absorp­
tion of indinavir, however, requires a low gastric pH 
value. Therefore, it is recommended that didanosine 
and indinavir should be administered with a mini­
mum time interval of 1 hour [71 ].
It is anticipated that concurrent administration of 
indinavir and ritonavir will lead to an increase in 
indinavir plasma concentrations due to inhibition of 
cytochrome P450 enzymes [71]. Concurrent adminis­
tration of indinavir and astemizole, terfenadine, quini- 
dine, cisapride, alprazolam, midazolam or triazolam 
may lead to increased concentrations of the coadmin­
istered drugs due to inhibition of their metabolism by 
indinavir [71].
Ritonavir
Ritonavir (ABT-538, Norvir®, Figure 4) is marketed by 
Abbott and was approved by the FDA in the USA for 
use alone or in combination with approved nucle­
oside analogues In patients with advanced HIV infec­
tion. Approval for patients with advanced HIV infec­
tion was based on data demonstrating delay in dis­
ease progression and reduction of mortality. Ritonavir 
was also approved by the FDA under its accelerated 
approval regulations for patients with early HIV Infec­
tion based on a beneficial effect on surrogate parame­
ters. In the European Union ritonavir was the first HIV 
protease inhibitor to be approved in August 1996 for 
use In combination with antiretroviral nucleoside ana­
logue^) In HIV-infected adult patients with advanced 
or progressive immunodeficiency [77].
Figure4
Molecular structure of ritonavir (Norvir®).
Table 5 Effects of Indinavir in combination with nucleoside analogues on CD4+ lymphocyte counts and HIV RNA load
Reference change in CD4+ lymphocyte count from baseiine change in HIV RNA ioad from baseline 
(cells/fjL) (10log units)
dose
(mg)
patients (N) change at week 
4 12 32 34 4 32 • 34
78 300 bid +80 +25 -0.78
400 bid +140 +70 -0.83
500 bid +100 +25 -0.97
600 bid +70 +230 -1.13 t O oo
79 200 tid +90 +137
300 tid +114 +140
200 qid +25 +60
300 qid +63 +59
80 400 tid 17 +90 +110 -1.80 -0.24
700 bid 13 +110 +267 -1.82 -0.74
Efficacy of ritonavir monotherapy
A randomised, double-blind, placebo-controlled 
phase I/ll study with ritonavir monotherapy was con­
ducted in 84 HIV infected patients with >50 CD4+ 
lymphocyte cells//vL and >10 pg/mL of p24 antigen 
[78], Patients were randomised to receive placebo, or 
ritonavir in a dosage of 300, 400, 500, or 600 mg bid. 
After 4 weeks of therapy the patients who received 
placebo were randomised to one of the four dosage 
regimens. From week 1 through 4 a decline in HIV 
RNA load and p24 antigen was observed in all ritona­
vir arms compared to placebo (Table 5). The largest 
decrease was seen in the highest dose-group. After 4 
weeks of therapy the CD4+ lymphocyte count was 
higher in patients receiving ritonavir compared to 
placebo. After 16 weeks of therapy HIV RNA levels in 
the 300 and 400 mg bid dose groups returned to 
baseline. During the 32-week follow-up of the study 
no significant differences in HIV RNA load between 
the 300 and 400 mg dose groups were observed at 
any timepoint. The 500 and 600 mg dose groups, 
however, showed a more sustained suppression of 
HIV RNA load; the load in the 500 mg dose group 
increased after week 20 and returned to baseline at 
week 32. After 32 weeks of therapy, a difference in 
HIV RNA load was observed between the 500 and 
600 mg dose groups; the decrease in HIV load after 
32 weeks of therapy was -0.81 10log units in the high­
est dose group. The maximal decrease in HIV RNA 
load in the 500 and 600 mg dose groups combined 
(17 patients) was -1.94 10log units after 8 weeks of 
therapy as assessed with a more sensitive HIV RNA 
assay. After 24 weeks of therapy the initial increase in 
the CD4+ lymphocytes in the 300 and 400 mg dose 
groups was lost and counts returned to baseline. The 
largest median increase (230 cells//jL) after 32 weeks 
of therapy was observed in the highest dose groups 
and this was greater than in the 500 mg dose-group 
[78].
A randomised, double-blind, placebo-controlled 
trial was conducted in 62 patients with CD4+ lympho­
cyte counts between 50-500 cells//vL and an HIV RNA
load of >25,000 copies/mL [79]. Patients were ran­
domised to receive placebo, or ritonavir in a dosage 
of 200 or 300 tid, or 200 or 300 mg qid. After 4 weeks 
of therapy patients who received placebo were ran­
domised to one of the four regimens. At day 15 a 
decrease in HIV RNA ioad was observed in all ritonavir 
arms compared to placebo, with maximal decreases 
ranging from 0.86 to 1.18 10log units. After 4 weeks 
of therapy the mean decline in HIV RNA load of all 
therapies combined was 0.83 10log units. After 12 
weeks of therapy a mean decline in HIV RNA level of 
0.5 10log units was observed as determined with the 
branched-chain DNA assay (lower limit of quantifica­
tion (LOQ) 10,000 copies/mL). A more sensitive assay 
(LOQ 400 copies/mL) was used to re-analyze the 
results in a subset of 20 patients. The mean decline in 
HIV RNA as measured by the latter assay at week 12 
was 1.1 10log units, with a maximal decline of 1.7 
1 °log units after 2 to 3 weeks. The duration of the 
antiviral effect was less sustained in the lowest (200 
mg tid) dose-group. The results on CD4+ lymphocytes 
are summarised in Table 5.
An open-label study was performed with two 
potentially maximum tolerated doses of ritonavir in
30 patients with >50 CD4+ lymphocyte cells/^L and a 
viral load >25,000 copies/mL (Table 5) [80].
The efficacy of ritonavir has also been assessed in 9 
HIV infected children with progressive disease or 
intolerance to other antiretroviral drugs in a phase l/ll 
study [81]. Four dose levels (250 to 400 mg/m2 bid) 
of the liquid formulation were studied. The first 12 
weeks ritonavir was given as monotherapy, after this 
period zidovudine and/or didanosine were added. By 
day 28 the CD4+ lymphocyte count had increased 
with 38 cells//vL in the lowest dose group. During the 
time of follow-up (median 6.3 weeks) the HiV RNA 
load declined with 1.5 10log units.
Efficacy of ritonavir in combination therapy
Preliminary data were presented from a study in 
which ritonavir or placebo is added to 1090 patients 
with <101 CD4+ lymphocytes/jwL-receiving ongoing 169
Pharmacy llhrld & Santa*
Table 6 Effects of ritonavir in combination with nucleoside analogues on CD4+ lymphocyte counts and HIV RNA load
Reference change in CD4+ lymphocyte counts 
from baseline (ceils/pi)
change in HIV RNA load 
(10loq units) from baseline
drug regimen patients (N) change at week change at week
(mq bid) 12 16 20 28 12 16 20 28
77 AZT 200a 116 +11 -0.42
RIT 600 118 +62 -1.03
RIT 600+AZT 200a 120 +35 -0.80
84 RIT 600+AZT 200a+DDC 0.75a 29 +141b +140d -2.36b -2.00c
85 RIT 600+A /1 300+3TC 150d 17 +78 -2.5
RIT 600+AZT 300+3TC 150e 16 +130 -2.7
a  t i d
b after 5 months of therapy 
c after 9 months of therapy
d patients started immediately with triple drug therapy
e zidovudine and lamivudine were added after three weeks of ritonavir monotherapy
Abbreviations: NR = not reported, 3TC = lamivudine, AZT - zidovudine, DDC - zalcitabine, RIT = ritonavir.
-a
O '
■n£fp5?r -
therapy with 0, 1, or 2 nucleoside analogues [82]. A 
significant reduction in the risk of developing a new 
AIDS-defining illness or death (relative risk 0.44, 95% 
confidence interval 0.34 to 0.56) and death alone 
(relative risk 0.57, 95% confidence interval 0.35 to
0.92) was observed in patients receiving ritonavir; 
median follow-up time was 6.1 months. In a 16-week 
substudy, virologic (159 patients) and immunologic 
(215 patients) surrogate markers of anti-HIV activity 
were followed [83]. For the ritonavir group the mean 
maximal decrease in HIV RNA load was 1.29 10log 
units. The peak increase in CD4+ lymphocyte count 
was 47 cells/^ /L. A greater clinical benefit for patients 
with >5.4 10log particles of HIV RNA/mL was 
observed compared to patients with >5.4 10log parti- 
cles/mL at baseline. The greatest effect of ritonavir 
therapy was seen in patients with >50 cells/ji/L. Thus, 
clinical benefit may be more pronounced with earlier 
therapeutic intervention with ritonavir.
356 HIV infected, antiretroviral naive patients with 
>200 CD4+ lymphocytes/ji/L and a mean HIV RNA 
level of 68,000 copies/mL were randomized to 
receive zidovudine monotherapy (200 mg tid), ritona­
vir monotherapy (600 mg bid) or a combination of 
both drugs (Table 6) [77]. Surprisingly, significant dif­
ferences favouring ritonavir monotherapy over com­
bination therapy were reported. However, analysis of 
ritonavir plasma concentrations revealed that these 
were higher in patients receiving monotherapy com­
pared to combination therapy. This was attributed to 
poor compliance in the combination therapy arm.
Ritonavir (1200 mg) was combined with zidovu­
dine (600 mg) and zalcitabine (2.25 mg/day) in an 
open-label study in 29 antiretroviral naive patients 
with <250 CD4+ lymphocytes/jivL (Table 6) [84]. The 
maximum decline in HIV RNA load and maximum 
increase in CD4+ lymphocyte count was observed Adverse effects 
after 5 months of therapy. The 10log value of infec­
tious blood cells/107 PBMCs reached a maximum
bid) and lamivudine (150 mg bid) were examined in 
an open-label, randomized, two-arm study [85], 
Patients started with either all three drugs simultane­
ously, or with ritonavir monotherapy for three weeks, 
followed by the addition of zidovudine and lamivu­
dine. As the rate of mutations is theoretically depen­
dent on the rate of viral turnover, zidovudine and 
lamivudine were administered after viral load had 
been suppressed by ritonavir in an attempt to 
decrease the risk of developing resistance to lamivu­
dine. Eligible patients had to be antiretroviral naive 
and had CD4+ lymphocyte counts >50 cells//A. and a 
HIV RNA load >30,000 copies/mL. Tonsillar biopsies 
were taken to compare tissue and plasma viral load. 
Results after 12 weeks of follow-up are summarized in 
Table 6. No statistically significant difference in 
decrease in HIV RNA load or increase in CD4+ lympho­
cyte counts was observed. In both treatment groups 
viral load became undetectable in 80% of the 
patients after 16 weeks of therapy [86]. Preliminary 
results indicate that HIV RNA load in tonsillar biopsies 
became undetectable in 4 patients after 24 weeks of 
therapy. Combination therapy with ritonavir plus 
saquinavir has been discussed before (Table 2).
Ritonavir in primary HIV infection
Combination therapy with ritonavir (600 mg bid) 
zidovudine (200 mg tid) plus lamivudine (150 mg 
bid) was started in 12 patients with acute HIV infec­
tion [87]. After 28 to 240 days of therapy viral load 
became undetectable in 11 of 12 patients. In all 
patients viral load became undetectable by PBMC 
coculture. Therapy is now planned for a minimum of 
1 year, after which lymphoid tissue will be assessed 
for presence of active viral replication.
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decline (-2.44 10log units) after 9 months of therapy.
The safety and efficacy of triple combination thera­
py with ritonavir (600 mg bid), zidovudine (300 mg
In a phase I/ll study of ritonavir in a dosage of 300, 
400, 500, or 600 mg bid, 85 to 100% of the patients
reported at least one adverse event [78]. The most 
pronounced adverse events were nausea, circumoral 
paraesthesia, and elevated levels of hepatic enzymes.
Asymptomatic elevation of cholesterol (30 to 40%) 
and triglycerides (200 to 300%) persisted through 
the 32 weeks of this study. Elevation of ASAT and 
ALAT were seen at the beginning of the study.
Resistance to ritonavir
Complete in vitro cross-resistance between indinavir 
and ritonavir has been reported [69]. Cross-resistance 
with saquinavir, however, appears to be relatively 
rare. Genotypic changes with wild-type valine of 
codon 82 changing to alanine or phenylalanine are 
observed in clinical studies [78]. With higher doses of 
ritonavir breakthrough in HIV replication is delayed in 
many patients. At lower doses, however, a more rapid 
return to baseline HIV RNA load is observed. The loss 
of effect is linked to stepwise, ordered accumulation 
of mutations in the protease gene [88]. High plasma 
concentrations of ritonavir appear to delay the onset 
of resistance by suppressing viral replication.
Dosage and administration
The currently recommended dosage of ritonavir is 
600 mg bid, either alone or in combination with 
nucleoside analogues. Due to the induction of its own 
metabolism [79], it is now recommended to increase 
ritonavir doses over several days at start of therapy, A 
widely accepted regimen is 300 mg bid (3 days), 400 
mg bid (3 days), and 500 mg bid (3 days). Thereafter, 
ritonavir is administered in the recommended regi­
men of 600 mg bid. Ritonavir should be taken with a 
meal. Ritonavir is available as 100 mg capsules. It is 
also available as a solution (80 mg/mL), Ritonavir cap­
sules and solution should be kept between 2-8 °C, but 
can be kept at room temperature for 7 days. Whether 
reduction of the dosage of ritonavir is necessary in 
patients with liver insufficiency is not clear yet.
Pharmacokinetics
The pharmacokinetics of ritonavir were studied in two 
groups of HIV-infected patients [89], Ritonavir was 
administered under fasting conditions in single oral 
doses of 100, 200, 400, 600, 800, and 1,000 mg. 
Cmax and AUC of ritonavir increased non-lineariy with 
the mean normalized (100 mg) Cmax and AUC 
increasing from 0.416 fjg/ml and 3.480 /vg*h/mL at
100 mg to 1.27 /vg/mL and 12.31 ¿vg*h/mL at 1,000 
mg, respectively. The mean Tmax ranged from 3.8 
hours for 100 mg to 3.1 hours for 1,000 mg. The 
nonlinear increase of Cmax and AUC was attributed to 
saturable first-pass metabolism. The major elimina­
tion pathway of ritonavir is by cytochrome P450-3A4 
and, to a lesser extent, cytochrome P450-2D6 related 
metabolism [77]. Four metabolites have been identi­
fied in humans and only one, the isopropylthiazole 
oxidation metabolite, has been found in the systemic 
circulation and seems to be as active as the parent 
compound [77]. After oral administration, 20% to 
40% of unchanged ritonavir is recovered in human 
faeces [77]. Renal clearance of ritonavir is less than 2 
mL/min. The half-life of ritonavir is approximately 3 
hours. Ingestion of 600 mg ritonavir with food 
increases the AUC by 63%, the Cmax by 34%, and 
delays the Tmax by 1.6 hours.
The pharmacokinetics of the currently recom­
mended dose (600 mg bid) in 10 HIV infected 
patients have been characterized [78]. A Cmax of 11.2 
jwg/mL after 3.3 h, an AUC of 60.8 ¿;g*h/mL and a
trough plasma concentration of 3.03 fjg/mL were 
reported. The half-life of ritonavir was 3.2 h with an 
apparent clearance of the drug of 8.9 L/h. With this 
recommended dose regimen ritonavir plasma con­
centrations were above the targeted effective concen­
tration (based on in vitro data, the functional 90% 
effective concentration, after adjustment for binding 
to protein, is 2.1 (jg/mL) [78].
Ritonavir is approximately 99% bound to plasma 
proteins [78]. Limited data in patients showed that 
ritonavir is present in extremely low concentrations in 
the cerebrospinal fluid, reflecting the free concentra­
tion in plasma [77], No effect on relative bioavailabil­
ity was detected when ritonavir oral liquid formula­
tion was administered with either water, Advera®, 
Ensure®, or chocolate milk in healthy volunteers [90]. 
The oral bioavailability in humans has not been 
reported. Ritonavir pharmacokinetics have not been 
studied in patients with hepatic or renal insufficiency. 
Subgroup analyses revealed a significant reduction of 
the AUC of 18% in smokers versus non-smokers. 
Another subgroup analysis of patients with high ver­
sus low body weight revealed that AUC values did not 
correlate with body weight [77].
Pharmacokinetic-pharmacodynamic relationships
In a phase l/II study sustained effects on CD4+ lym­
phocyte counts and viral RNA were observed only in 
patients in the highest ritonavir dose groups [78]. In 
these patients the mean trough concentration 
exceeded the target concentration of 2.1 fjg/mL. 
Thus, a relationship between ritonavir trough concen­
tration and effect on surrogate parameters might 
exist.
A relationship between low ritonavir trough con­
centrations and the emergence of viral strains resist­
ant to the drug has been reported [91 ].
As discussed before, ritonavir monotherapy result­
ed in improved antiviral efficacy compared with riton­
avir/zidovudine combination therapy [77]. When 
ritonavir plasma concentrations were assessed, it 
appeared that patients in the monotherapy arm had 
higher ritonavir plasma concentrations. This might 
indicate, that higher ritonavir plasma concentrations 
are correlated with superior effects on surrogate 
parameters.
These indications of pharmacokinetic-pharmacody- 
namic relationships suggest that monitoring of ritona­
vir pharmacokinetics may assist in achieving optimal 
antiretroviral therapy.
Drug interactions
The effect of multiple doses ritonavir on the pharma­
cokinetics of single doses of the combination trimeth­
oprim and sulfamethoxazole has been investigated 
[92]. The AUC of sulfamethoxazole decreased with 
19.8% in the presence of ritonavir, the half-life 
decreased by 18%, whilst no significant effect was 
observed on Cmax. The AUC of the N-acetyl metab­
olite of sulfamethoxazole was decreased with 10.4%. 
The AUC of trimethoprim was increased by 19.9%, 
the half-life was increased with 20%. and the Croav
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did not differ when coadministered with ritonavir. 
The increased clearance of sulfamethoxazole might 
be caused by induction of N-glucuronidation by 
ritonavir. These minor changes in pharmacokinetics 
were considered to be not clinically relevant.
The effect of ritonavir on the pharmacokinetics of 
ethinyl estradiol has been studied in 23 healthy 
female volunteers [93], The ethinyl estradiol Cmax was 
decreased by 32%, the AUC was decreased with 
41%, and the terminal half-life was increased with
31 %  when ritonavir was coadministered. These 
changes might be caused by the induction of glucu- 
ronrdation and/or cytochrome P450 hydroxylation. 
Use of alternative contraceptive measures or doubling 
the contraceptive dose should be considered when 
ritonavir and oral contraceptives are concurrently 
used.
The pharmacokinetics of rifabutin and its active 
metabolite 25-O-desacetyl-rifabutin were assessed 
with administration of ritonavir or placebo in a dou­
ble-blind, parallel group study [94]. Concurrent riton­
avir dosing increases the Cmin, Cmax, and AUC of 
rifabutin by 6-, 2.5-, and 4-fold, respectively. The val­
ues for Cmin, Cmax, and AUC of the active metabolite 
increased by 200-, 16-, and 35-fold, respectively. 
These changes are probably caused by the inhibition 
of metabolism of both rifabutin and its active metab­
olite by ritonavir. Because of these increased plasma 
concentrations and of the increased risk of rifabutin- 
associated adverse effects (arthralgia, joint stiffness, 
uveitis, and leucopenia) [95], an alternative to rifabu­
tin is recommended when ritonavir and rifabutin are 
coadministered.
The steady-state Cmax, Cmjn, and AUC of theophyl­
line decreases by 32, 57, and 43%, respectively, when 
ritonavir is coadministered [96]. The haJf-life of theo­
phylline decreases from 8.4 h to 3.6 h. These effects 
are time-dependent, probably due to increased cyto­
chrome P450-1A2 activity after multiple doses of 
ritonavir. Thus, increasing the theophylline dose and 
monitoring theophylline concentrations is necessary 
when ritonavir is coadministered.
The effect of multiple doses of ritonavir on the 
pharmacokinetics of single doses of desipramine and 
2-hydroxy desipramine was investigated [97], The 
AUC, half-life, and Cmax of desipramine increased 
2.45-, 2-fold, and with 22.1%, respectively. The 2- 
hydroxy metabolite to parent ratio for AUC and Cmax 
decreased by 67% in both cases. The pharmacokinet­
ics of ritonavir were not affected. Thus, it is advised to 
start with lower doses desipramine (or other tricyclic 
antidepressants) and to monitor tricyclic antidepress­
ant concentrations when coadministered with ritona­
vir.
Coadministration of zidovudine (200 mg tid) and 
ritonavir (300 mg qid) showed no influence on ritona­
vir pharmacokinetics [77]. However, zidovudine Cmax 
and AUC were reduced by 27% and 25%, respective­
ly, when ritonavir was coadministered. A similar effect 
on didanosine Cmax (16% reduction) and AUC (13% 
reduction) has been observed [77], Though statisti­
cally significant, no dose adjustment of didanosine is 
advised.
Clarithromycin exposure was increased with con­
comitant ritonavir administration due to inhibition of 
its active metabolite formation [77]. The increase of 
the parent drug is, however, counterbalanced by 
decreased active metabolite formation. Thus, no dos­
age reduction of clarithromycin is necessary in 
patients with normal renal function. When coadminis­
tered with ritonavir, a maximum dose of 1 gram of 
clarithromycin is recommended.
The effect of fluconazole (400 mg on day 1, 200 
mg on days 2 to 5) on ritonavir (200 mg qid) pharma­
cokinetics has been assessed [98]. Ritonavir Cmax and 
AUC were significantly increased with coadministra­
tion of fluconazole. However, these changes were less 
than 15% and were not considered to be clinically rel­
evant. Plasma half-life and Tmax of ritonavir were not 
affected.
The pharmcicokinetic interaction between ritonavir 
and saquinavir has been discussed before.
Furthermore, an extensive list of drugs that could 
lead to increased concentrations of the coadminis­
tered drug due to inhibition of their metabolism by 
ritonavir exists [99], These drugs include alprazolam, 
amiodarone, astemizole, calcium-channel blocking 
agents, carbamazepine, ciclosporin, cisapride, cloraz- 
epate, dexamethasone, diazepam, encainide, ergota- 
mine, erythromycin, flecainide, fluoxetine, fluraze- 
pam, itraconazole, ketoconazole, quinidine, lorata- 
dine, mefloquine, midazolam, paroxetine, pethidine, 
pimozide, piroxicam, prednisolone, propafenone, 
propoxyphene, sertraline, terfenazine, trazodone, tri­
azolam, warfarin, and zolpidem.
Conclusion
Enormous efforts have been made in the search for 
drugs to treat HIV infection for over a decade now. 
After the crystal structure of the HIV-encoded pro­
tease enzyme had been elucidated, computer-aided 
drug design played a pivotal role in the development 
of new compounds that inhibit this viral enzyme that 
is responsible for H(V maturation and infectivity. 
Promising representatives of these compounds have 
recently found their way to patients.
Protease inhibitors show a powerful sustained sup­
pression of HIV replication, especially when used in 
combination therapy regimens, and have already 
proven to be a valuable contribution to the armamen­
tarium of drugs to treat HIV infection. Though these 
agents have become available only recently, combi­
nation therapy of a protease inhibitor plus two reverse 
transcriptase inhibitors has already become standard 
antiretroviral therapy in many countries. Protease 
inhibitors that are now available are saquinavir, indin­
avir and ritonavir. In this review issues involving clini­
cal results, adverse effects, resistance, dosage and 
administration, clinical pharmacokinetics, pharma­
cokinetic-pharmacodynamic relationships, and drug- 
drug interactions are discussed.
Protease inhibitors have in common that drug 
compliance is of enormous importance; HIV strains 
with resistance to these compounds will develop inev­
itably in patients who do not take their medication as 
prescribed. Indications of pharmacokinetic-pharma­
codynamic relationships have been found; low expo­
sure to protease inhibitors may lead to suboptimal or 
absence of immunological and virological response. 
Furthermore, a vast amount of (potential) drug-drug 
interactions has been identified, making protease 
inhibitors a good candidate for pharmacokinetic drug 
monitoring in patients.
New representatives of this class of compounds are 
being evaluated in clinical trials and are likely to be 
licensed in the following years.
The importance of protease inhibitors in clinical prac­
tice and the characteristics of the different representa-
tives is likely to become more clear in the following
years.
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